Lipocine Inc. (NASDAQ:LPCN)’s share price was down 2.2% during trading on Thursday . The stock traded as low as $3.53 and last traded at $3.55, with a volume of 53,804 shares changing hands. The stock had previously closed at $3.63.

Separately, Canaccord Genuity reiterated a “buy” rating and set a $6.00 price objective (down from $15.00) on shares of Lipocine in a research report on Saturday, July 2nd.

The company’s 50-day moving average is $3.67 and its 200 day moving average is $7.78. The stock’s market cap is $66.09 million.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Equities research analysts anticipate that Lipocine Inc. will post ($1.31) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Lipocine stock. Dimensional Fund Advisors LP boosted its stake in Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned about 1.49% of Lipocine worth $3,508,000 as of its most recent SEC filing.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.